Avid Bioservices, Inc. provided revenue guidance for fiscal 2023. The company provides revenue guidance for fiscal 2023 of $140 million to $145 million, a 17% - 21% increase over fiscal 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.44 USD | -0.67% | -2.23% | +14.46% |
Apr. 30 | RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating | MT |
Apr. 29 | Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.46% | 472M | |
+1.43% | 94.45B | |
-0.66% | 38.9B | |
-13.57% | 32.56B | |
+70.85% | 28.34B | |
-12.73% | 15.98B | |
-2.15% | 13.82B | |
-13.59% | 11.34B | |
+158.88% | 9.81B | |
-52.04% | 9.67B |
- Stock Market
- Equities
- CDMO Stock
- News Avid Bioservices, Inc.
- Avid Bioservices, Inc. Provides Revenue Guidance for Fiscal 2023